Publications

  1. Meagher KM, Cummins NW, Bharucha AE, Badley AD, Chlan LL, Wright RS. COVID-19 Ethics and Research. Mayo Clin Proc. 2020 Jun; 95 (6):1119-1123 Epub 2020 Apr 24
    View PubMed
  2. Meagher KM, Curtis SH, Gamm KO, Sutton EJ, McCormick JB, Sharp RR. At a Moment's Notice: Community Advisory Board Perspectives on Biobank Communication to Supplement Broad Consent. Public Health Genomics. 2020 May 12; 1-13 [Epub ahead of print]
    View PubMed
  3. Waltz M, Meagher KM, Henderson GE, Goddard KA, Muessig K, Berg JS, Weck KE, Cadigan RJ. Assessing the implications of positive genomic screening results. Per Med. 2020 Mar; 17 (2):101-109 Epub 2020 Mar 03
    View PubMed
  4. Meagher KM, Allyse MA, Master Z, Sharp RR. Reexamining the Ethics of Human Germline Editing in the Wake of Scandal. Mayo Clin Proc. 2020 Feb; 95 (2):330-338
    View PubMed
  5. Olson JE, Ryu E, Hathcock MA, Gupta R, Bublitz JT, Takahashi PY, Bielinski SJ, St Sauver JL, Meagher K, Sharp RR, Thibodeau SN, Cicek M, Cerhan JR. Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile. BMJ Open. 2019 Nov 6; 9 (11):e032707 Epub 2019 Nov 06
    View PubMed
  6. Corneli A, Meagher K, Henderson G, Peay H, Rennie S. How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS Behav. 2018 Dec 10 [Epub ahead of print]
    View PubMed
  7. Henderson GE, Waltz M, Meagher K, Cadigan RJ, Jupimai T, Isaacson S, Ormsby NQ, Colby DJ, Kroon E, Phanuphak N, Ananworanich J, Peay HL. Going off antiretroviral treatment in a closely monitored HIV "cure" trial: longitudinal assessments of acutely diagnosed trial participants and decliners. J Int AIDS Soc. 2019 Mar; 22 (3):e25260
    View PubMed
  8. Juengst ET, Henderson GE, Walker RL, Conley JM, MacKay D, Meagher KM, Saylor K, Waltz M, Kuczynski KJ, Cadigan RJ. Is Enhancement the Price of Prevention in Human Gene Editing? CRISPR J. 2018 Dec; 1:351-354 Epub 2018 Nov 26
    View PubMed
  9. Meagher KM, Berg JS. Too much of a good thing? Overdiagnosis, or overestimating risk in preventive genomic screening. Per Med. 2018 Sep; 15 (5):343-346 Epub 2018 Sept 27
    View PubMed
  10. Meagher KM, Juengst ET, Henderson GE. Grudging Trust and the Limits of Trustworthy Biorepository Curation. Am J Bioeth. 2018 Apr; 18 (4):23-25
    View PubMed
  11. Henderson GE, Peay HL, Kroon E, Cadigan RJ, Meagher KM, Jupimai T, Gilbertson A, Fisher J, Ormsby NQ, Chomchey N, Phanuphak N, Ananworanich J, Rennie S. Ethics of treatment interruption trials in HIV cure research: Addressing the conundrum of risk/benefit assessment Journal of Medical Ethics. 2017.
  12. Meagher KM, McGowan ML, Settersten RA, Fishman JR, Juengst ET. Precisely where are we going? Charting the new terrain of precision prevention. Annual Review of Genomics and Human Genetics. 2017; 18:369-387.
  13. Meagher KM, Lee LM. Public Health Perspectives and Ethical, Legal, and Social Issues: Integrating public health and public bioethics. Public Health Reports. 2016; 131(1):44-51.
  14. Meagher KM, Spector-Bagdady K. Present lessons from past infractions: STD research in Guatemala in the 1940s as an ethics case study Teaching Ethics. 2014; 14(2):53-76.
  15. Meagher KM. Considering virtue: Public health and clinical ethics Journal of Evaluation in Clinical Practice. 2011; 17(5):888-893.
  16. Campo-Engelstein L, Meagher KM. Costa Rica's white legend: How racial narratives undermind the values of its health care system. Developing World Bioethics. 2011; 11(2):9-107.